Cardiac Tissue Microsurgical Tool for Targeted Neuromodulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cardiac disease treatments, particularly those involving beta-receptor blockade, cause indiscriminate effects on cardiac structures and organs, leading to severe side effects and complications.
Innovation Solution
Development of a microsurgical tool with a microfinger and sensing tip for monitoring and modulating electrophysiological activity within body lumens, including guidewires for nerve monitoring, ablation, and neuromodulation, allowing precise intervention and minimization of side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic beta blockade is used to treat cardiac disease, then cardiac function is improved, but side effects increase due to indiscriminate effects on all cardiac structures and organs
Solution Approach 1:
The patent divides the treatment approach from systemic (affecting all cardiac structures) to localized (affecting specific target tissues only). The catheter delivery system enables segmented delivery of beta-blocking agents to specific cardiac regions, allowing treatment of pathological tissues while preserving normal cardiac structures and avoiding systemic side effects
Solution Approach 2:
The patent applies local quality by delivering beta-blocking therapy directly to specific cardiac tissues through catheter-based targeted delivery. This enables different parts of the cardiac system to have different treatment states - pathological regions receive beta blockade while normal regions remain unaffected, thus improving treatment efficacy while minimizing side effects
2Reliability
If beta blockade is applied to treat heart failure, then ventricular muscle function is improved, but arrhythmia risk increases due to bradyarrhythmias
Solution Approach 1:
The catheter-based delivery system segments the treatment to target only pathological ventricular muscle tissue while avoiding normal conduction tissues and pacemaker cells. This selective delivery prevents beta blockade from affecting cardiac rhythm centers, thereby treating heart failure without inducing bradyarrhythmias
Solution Approach 2:
The patent creates local quality differentiation where pathological myocardium receives beta-blocking treatment while normal cardiac structures including conduction systems remain unaffected. This localized approach maintains normal heart rhythm while improving heart failure symptoms
3Reliability
If systemic beta blockade is administered, then cardiac disease symptoms are reduced, but quality of life decreases due to intolerable side effects
Solution Approach 1:
The patent segments the delivery system to target only diseased cardiac tissues, preventing beta-blocking agents from reaching normal organs and tissues. This eliminates systemic side effects such as depression, impotence, and fatigue while maintaining effective disease symptom control in the target region
Solution Approach 2:
By creating localized beta blockade in diseased tissues while leaving normal tissues unaffected, the patent achieves effective symptom control without the quality of life deterioration caused by systemic side effects. Patients experience disease benefit without intolerable adverse effects
Data Source
AI summary
Systems, devices, and methods for performing precise treatment, mapping, and/or testing of tissues are disclosed. Systems, devices, and methods for administering an agent to one or more a precise regions within a tissue mass are disclosed. Systems, devices, and methods for treating targeted regions within a tissue mass are disclosed. Systems, devices, and methods for identifying, localizing, monitoring neural traffic in the vicinity of, quantifying neural traffic in the vicinity of, and mapping neural traffic near targeted regions within a tissue mass are disclosed.